1 of 1
Story summary
- U.S. President Donald Trump urged Congress to codify his Most Favored Nation (MFN) drug pricing initiative during the State of the Union.
- He cited recent deals with pharmaceutical companies that he said delivered price reductions for patients.
- Despite some Republican support, backing appears unlikely as Republicans resist intervention and some Democrats question deal confidentiality.
- Drugmakers' lobbyists oppose codifying price controls, and skepticism remains about the initiative's viability and free-market alignment.
